TB-500 Dosing and Tracking: How Research Protocols Are Structured

TB-500 (a synthetic fragment of Thymosin Beta-4) is most commonly researched at a loading phase of 2-2.5mg twice weekly for 4-6 weeks, then a maintenance dose of around 2mg every 1-2 weeks. People running self-experiments log each dose, site, and changes in joint comfort, range of motion, and recovery — both to evaluate the protocol and to catch side effects early.

Worth saying clearly up front: TB-500 is not FDA-approved for human use. Most data comes from animal studies and user reports. The information here describes how the research community typically structures protocols — not medical advice. If you're considering it, talk to a doctor who actually works with peptides.

How people structure a TB-500 protocol

There's no single accepted protocol, but a few patterns repeat in user reports:

• Loading phase: 2-2.5mg, two injections per week (e.g. Monday and Thursday) for 4-6 weeks
• Maintenance phase: ~2mg once every 1-2 weeks, often for another 4-8 weeks
• Route: Subcutaneous in the abdomen for systemic effects, or intramuscular near the area of interest
• Stacking: Frequently combined with BPC-157, with users theorising the two work on different recovery pathways

Because the half-life is reported as relatively long compared to BPC-157, weekly or twice-weekly dosing is more common than daily. That's a meaningful difference if you're tracking — fewer injections per week means each data point carries more weight.

What to track during a cycle

The whole point of logging is to know whether the protocol actually does something for you. Useful inputs:

• Dose and time — exact mg, time of injection, which side
• Injection site — rotating sites helps spot localised irritation
• Subjective symptoms — joint pain on a 1-10 scale, range of motion, stiffness, sleep, energy
• Objective markers — grip strength, lift numbers, mobility tests, anything you can repeat the same way each week
• Side effects — fatigue, headaches, lethargy, injection-site reactions

A logbook beats memory. Many users open Trace, log the dose in a few seconds, and add a short symptom note alongside it. Everything stays on-device behind Face ID, so research-peptide logs aren't sitting in a cloud sync somewhere.

Common pitfalls

The most frequent mistake is changing too many variables at once — starting TB-500 while also adding BPC-157, modifying training, and dropping a supplement in the same week. If something improves, you won't know which change moved the needle. Isolating one variable per cycle gives you data you can actually use.

Reconstitution math is the second pitfall. A 5mg vial reconstituted with 2.5ml of bacteriostatic water yields 2mg/ml, so a 2mg dose is 1.0ml on an insulin syringe. Working it out once at the start of a vial and writing it down avoids redoing the math under fluorescent bathroom lighting.

Storage is the third. Reconstituted TB-500 should be refrigerated and is generally considered stable for around 30 days, though many users use it inside two weeks for peace of mind.

Frequently Asked Questions

How is TB-500 different from BPC-157?

Both are research peptides studied for tissue repair, but they're thought to act through different mechanisms — BPC-157 on local healing and angiogenesis, TB-500 on cell migration and inflammation. They're often stacked for that reason. Neither has approved human use.

How long until users report noticing anything?

Reports vary widely. Some describe changes in the first two to three weeks of a loading phase, others not until week four or five, and some report nothing at all. Without controlled human data, individual response and careful tracking are the only meaningful measures.

What side effects do users most commonly mention?

The most frequently reported side effects in user logs are lethargy or "head fog" in the days after a dose, mild headaches, and injection-site irritation. Long-term human safety data does not exist, so anyone running a protocol should monitor closely and stop if something feels off. A doctor is the right person to consult, not a forum thread.